Postdoc Position in Cardiovascular Research
A postdoctoral position in the area of cardiovascular biology and cardiomyopathy is available in the lab of professor Ching-Pin Chang at Albert Einstein College of Medicine in New York. The primary research focus of the lab is to understand the molecular and genetic mechanisms of heart development and disease, with special emphasis on cardiomyopathy. Specific areas of interest include the genetic/epigenetic and noncoding RNA mechanism of cardiomyopathy (myocytes, endothelial cells, and fibroblasts). Chang lab’s publications include Nature (PMID: 25119045; 20596014; 25119037; 20130577), Cell (PMID: 15339668); Circulation Research (PMID: 18723445, 21293009), PNAS (PMID: 23319608; 27601681), Nature Communications, PMID: 28924218; 29215012), Developmental Cell (PMID: 23602386, 20816797), Annual Review Physiology (PMID: 22035349), Nature Review Cardiology (PMID: 25855606).
More description of the PI and work is on the next page.
Recent PhD graduates (or equivalents) with trainings in any field of biology are welcome to apply. Candidates with experience in cardiovascular research using mouse models and strong background in molecular biology will be given preference. Applicants with additional qualifications in animal heart surgeries are encouraged apply. The qualified candidates are expected to be self-motivated and team-oriented. Albert Einstein College of Medicine provides postdoctoral trainees with excellent work environment and affordable housing for individuals and families. The positions are available up to four years and supported by the NIH funding, with salaries/benefits according to the NIH and institutional guidelines.
Interested candidates are invited to submit a cover letter describing previous research experience and career goals, curriculum vitae, along with names of three references to:
Ching-Pin Chang, MD, PhD
Email: [email protected]
Department of Genetics
Albert Einstein College of Medicine
Bronx, NY 10461
Our laboratory is in the Department of Genetics at the Albert Einstein College of Medicine in New York City. Einstein is one of the nation’s premier institutions for medical education, basic research and clinical investigation. Forbes ranked Einstein in the top overall nationally among midsize employers, 3rd within the education category in New York State and 9th nationally among all midsize education employers. The Albert Einstein College of Medicine is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. Einstein seeks candidates whose skills, and personal and professional experience, have prepared them to contribute to our commitment to diversity and excellence, and the communities we serve.
Principal Investigator
Dr. Chang is a well-known physician-scientist for his groundbreaking work on the epigenetics and long noncoding RNA mechanism of heart disease. His work includes high-profile publications in Nature, Cell, Science, Developmental Cell, Development, Proceedings of National Academy of Sciences, and Circulation Research. Dr. Chang won many awards and grant supports from National Institute of Health (NIH) and many professional societies and foundations. He received his research and clinical training at Stanford University and Harvard Medical School. He held tenured Professorships, Directorships, or Endowed Chair of Cardiology in institutes he served, including Stanford University, Krannert Institute of Cardiology, and Albert Einstein College of Medicine. Besides 15 years of independent academic research, he has served for over four years as an executive in pharmaceutical and biotech companies to direct translational research and pipeline development for cardiomyopathy and heart failure.
Dr. Chang is an NIH-funded researcher, an AHA National Scientist and Established Investigator, and an elected member of American Society for Clinical Investigation. Dr. Chang’s primary research interest resides in developmental biology and heart failure. His cardiac research began from defining molecular interactions and signaling between different cell lineages during cardiac organogenesis in embryos. His studies of developmental biology led to several important discoveries and insights in regenerative medicine and the pathogenesis of congenital heart disease (Cell 2004, Circ. Res 2008, Dev. Cell 2008 & 2013, Nature 2006 & 2010). From his developmental studies, Dr. Chang observed a mechanistic link at the epigenetic and gene regulation level between fetal heart development and adult heart failure (Nature 2010). He then applied the insights to adult heart failure, studying epigenetics, chromatin, and transcription regulation in the failing heart. Dr. Chang’s epigenetics studies let him to the discovery of a cardioprotective long, non-coding RNA (lncRNA) that inhibits pathogenic chromatin remodeling and adverse gene reprogramming to prevent heart failure (Nature 2014). This provided the first example of lncRNA-chromatin remodeling interface for chromatin/RNA biology and heart failure, and this work was highlighted by NIH in a special report and selected by the AHA in 2015 as the leading discovery. Dr. Chang’s work is not limited to cardiomyocyte biology, and his lab has developed expertise in the study of cardiac endothelial cells and fibroblasts in the pathogenesis of heart failure (Nature Comm 2016, PNAS 2016). He discovered many new heart failure therapeutic targets and showed efficacy of small molecule-, RNA- or antibody-based molecules against those targets.
